Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLX51107 in advanced hematological malignancies and solid tumors
NCT02683395Phase 1Terminated
- Sponsor
- Plexxikon Inc.
- Start
- Mar 2016
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PLX51107 in solid tumor, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and 1 more (2 arms), sponsored by Plexxikon Inc. Primary endpoints: Safety of PLX51107 as measured by adverse events and serious adverse events at 1 year, Area under the concentration-time curve of PLX51107 at 1 year and 3 more. Started Mar 2016; status: terminated.
02
Drugs
PLX51107
03
Conditions
solid tumoracute myeloid leukemia (AML)myelodysplastic syndrome (MDS)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02683395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02683395.